{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:30:14Z","timestamp":1789097414324,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.cca.2025.120207","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:55:35Z","timestamp":1740156935000},"page":"120207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Optimizing HIV testing: Comparing diagnostic signatures and assay performance in ART-treated and general screening populations"],"prefix":"10.1016","volume":"570","author":[{"given":"Qian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2025.120207_b0005","unstructured":"WHO. The global health observatory of HIV. 2024. https:\/\/www.who.int\/data\/gho\/data\/themes\/hiv-aids (accessed 6 Jun2024)."},{"key":"10.1016\/j.cca.2025.120207_b0010","unstructured":"United Nations 70\/266. Political Declaration on HIV and AIDS: On the Fast Track to Accelerating the Fight against HIV and to Ending the AIDS Epidemic by 2030 | UNAIDS. https:\/\/www.unaids.org\/en\/resources\/documents\/2016\/2016-political-declaration-HIV-AIDS (accessed 13 Dec2024)."},{"key":"10.1016\/j.cca.2025.120207_b0015","unstructured":"Global AIDS Strategy 2021-2026 \u2014 End Inequalities. End AIDS. | UNAIDS. https:\/\/www.unaids.org\/en\/resources\/documents\/2021\/2021-2026-global-AIDS-strategy (accessed 1Dec2024)."},{"key":"10.1016\/j.cca.2025.120207_b0020","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1056\/NEJMcp1915826","article-title":"HIV Infection \u2014 Screening, Diagnosis, and Treatment","volume":"384","author":"Saag","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2025.120207_b0025","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/500215","article-title":"Seroreversion in Subjects Receiving Antiretroviral Therapy during Acute\/Early HIV Infection","volume":"42","author":"Hare","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cca.2025.120207_b0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/cid\/ciw365","article-title":"Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology","volume":"63","author":"de Souza","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.cca.2025.120207_b0035","doi-asserted-by":"crossref","first-page":"e00757","DOI":"10.1128\/JCM.00757-19","article-title":"Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection","volume":"57","author":"Manak","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.cca.2025.120207_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107222","article-title":"Suppressed HIV antibody responses following exposure to antiretrovirals-evidence from PrEP randomized trials and early antiretroviral treatment initiation studies","volume":"148","author":"Avelino-Silva","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.cca.2025.120207_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjid.2024.103848","article-title":"HIV acute infection and long-term undisclosed HIV status among blood donors from the highly endemic Amazonas state, located in the Brazilian Amazon","volume":"28","author":"de Souza","year":"2024","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.cca.2025.120207_b0050","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1111\/trf.16571","article-title":"Undisclosed HIV status and antiretroviral therapy use among South African blood donors","volume":"61","author":"van den Berg","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.cca.2025.120207_b0055","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/v14020277","article-title":"Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China","volume":"14","author":"Huang","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.cca.2025.120207_b0060","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2352-3018(17)30043-7","article-title":"Comparing dynamic monitoring strategies based on evolving CD4 cell counts in virologically suppressed HIV-positive individuals on cART: a prospective observational study in high-income countries","volume":"4","author":"Caniglia","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cca.2025.120207_b0065","doi-asserted-by":"crossref","first-page":"20061","DOI":"10.7448\/IAS.18.1.20061","article-title":"CD4 changes among virologically suppressed patients on antiretroviral therapy: a systematic review and meta-analysis","volume":"18","author":"Ford","year":"2015","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.cca.2025.120207_b0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jcv.2017.04.014","article-title":"Relevance of cutoff on a 4th generation ELISA performance in the false positive rate during HIV diagnostic in a low HIV prevalence setting","volume":"92","author":"Chac\u00f3n","year":"2017","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.cca.2025.120207_b0075","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/QAD.0000000000003507","article-title":"Increased risk of false-positive HIV ELISA results after COVID-19","volume":"37","author":"Alfie","year":"2023","journal-title":"AIDS"},{"key":"10.1016\/j.cca.2025.120207_b0080","unstructured":"Acquired Immunodeficiency Syndrome and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome (2024 edition). Chinese Journal of Infectious Diseases; 42: Epub for ahead. https:\/\/rs.yiigle.com\/cmaid\/1501644 (accessed 6 Jun2024)."},{"key":"10.1016\/j.cca.2025.120207_b0085","unstructured":"National Center for AIDS\/STD Control and Prevention, China CDC. National Guideline for Detection of HIV\/AIDS. https:\/\/ncaids.chinacdc.cn\/zxzx\/zxdteff\/202005\/t20200518_216798.htm (accessed 13 Dec2024)."},{"key":"10.1016\/j.cca.2025.120207_b0090","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12250-019-00130-3","article-title":"Prevalence of HIV Indeterminate Western Blot Tests and Follow-up of HIV Antibody Sero-Conversion in Southeastern China","volume":"34","author":"Wu","year":"2019","journal-title":"Virol. Sin."},{"key":"10.1016\/j.cca.2025.120207_b0095","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention (U.S.) et al. Laboratory testing for the diagnosis of HIV infection: updated recommendations. Centers for Disease Control and Prevention, 2014. https:\/\/doi.org\/10.15620\/cdc.23447.","DOI":"10.15620\/cdc.23447"},{"key":"10.1016\/j.cca.2025.120207_b0100","unstructured":"2018 Quick reference guide: Recommended laboratory HIV testing algorithm for serum or plasma specimens. https:\/\/stacks.cdc.gov\/view\/cdc\/50872 (accessed 13 Dec2024)."},{"key":"10.1016\/j.cca.2025.120207_b0105","unstructured":"Technical update for HIV nucleic acid tests approved for diagnostic purposes. https:\/\/stacks.cdc.gov\/view\/cdc\/129018 (accessed 13 Dec2024)."},{"key":"10.1016\/j.cca.2025.120207_b0110","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1086\/605446","article-title":"Persistent low level viremia in HIV-1 elite controllers and relationship to immunologic parameters","volume":"200","author":"Pereyra","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cca.2025.120207_b0115","article-title":"Clinical, epidemiological, and drug resistance insights into HIV-positive patients in Meizhou, China","volume":"13","author":"Liu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.cca.2025.120207_b0120","article-title":"Anti-HIV-1 antibodies based confirmatory results in Wuhan, China, 2012-2018","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2025.120207_b0125","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1128\/JCM.01089-14","article-title":"Performance of the Liaison XL Murex HIV Ab\/Ag test on clinical samples representing current epidemic HIV variants","volume":"52","author":"Lemee","year":"2014","journal-title":"J. Clin. Microbiol."},{"issue":"Suppl 1","key":"10.1016\/j.cca.2025.120207_b0130","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.jcv.2011.09.023","article-title":"Performance evaluation of the Bio-Rad Laboratories GS HIV Combo Ag\/Ab EIA, a 4th generation HIV assay for the simultaneous detection of HIV p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2 in human serum or plasma","volume":"52","author":"Bentsen","year":"2011","journal-title":"J. Clin. Virol."},{"issue":"Suppl 1","key":"10.1016\/j.cca.2025.120207_b0135","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.jcv.2011.09.010","article-title":"Evaluation of the performance of the Abbott ARCHITECT HIV Ag\/Ab Combo Assay","volume":"52","author":"Chavez","year":"2011","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.cca.2025.120207_b0140","unstructured":"Clinical Quality Assessment of HIV Antibody Diagnostic Reagents, 2019. https:\/\/ncaids.chinacdc.cn\/zxzx\/zxdteff\/201912\/t20191218_207630.htm (accessed 13 Dec2024)."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125000865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125000865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T17:14:41Z","timestamp":1741367681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125000865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":28,"alternative-id":["S0009898125000865"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120207","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing HIV testing: Comparing diagnostic signatures and assay performance in ART-treated and general screening populations","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120207"}}